By Fineline Cube Alebund Pharmaceuticals (HKG: 9637) announced that the first patient has been randomized and dosed in its global Phase IIb multi-regional clinical trial (MRCT, NCT06712654) evaluating AP306, a first-in-class oral pan-phosphate transporter inhibitor, in hyperphosphatemia patients undergoing maintenance hemodialysis. The trial is being conducted across multiple clinical sites in the United States and China, with co-sponsorship from R1 Therapeutics, Inc.
Clinical Trial Details
| Item | Detail |
|---|---|
| Trial Phase | Phase IIb |
| Trial Type | Multi-regional clinical trial (MRCT) |
| ClinicalTrials.gov ID | NCT06712654 |
| Patient Population | Hyperphosphatemia patients on maintenance hemodialysis |
| Geographic Scope | United States and China |
| Co-Sponsor | R1 Therapeutics, Inc. |
| Milestone | First patient randomized and dosed (July 21, 2026) |
Drug Profile & Mechanism of Action
- Compound: AP306 (EOS789) – first-in-class oral pan-phosphate transporter inhibitor
- Origin: Originally discovered by Chugai Pharmaceutical Co., Ltd.
- Rights: Alebund holds exclusive global rights for development, manufacturing, and commercialization
- Mechanism: Unlike traditional phosphate binders that passively bind free phosphate in the gut, AP306 actively reduces intestinal phosphate transport by broadly inhibiting three key intestinal phosphate transporters: NaPi-IIb, PiT-1, and PiT-2
- Therapeutic Differentiation: Represents a novel mechanistic approach to hyperphosphatemia management, potentially offering superior efficacy compared to current standard-of-care phosphate binders
Market Opportunity
Hyperphosphatemia affects approximately 70% of end-stage renal disease (ESRD) patients on dialysis, representing a significant unmet medical need. Current treatment options are limited to phosphate binders with suboptimal adherence due to high pill burden and gastrointestinal side effects. AP306’s targeted mechanism could address these limitations while providing more effective phosphate control.
Strategic Partnership
The collaboration between Alebund Pharmaceuticals and R1 Therapeutics leverages complementary expertise in nephrology drug development and global clinical trial execution. This partnership accelerates the development timeline and enhances the probability of regulatory success across major markets.
Company Background
Alebund Pharmaceuticals (HKG: 9637) is a Hong Kong-listed biopharmaceutical company focused on developing innovative therapies for renal and metabolic disorders. The company’s strategic licensing approach enables rapid pipeline advancement through partnerships with established pharmaceutical organizations.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations for AP306. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech